What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Breast cancer
Hope S. Rugo mainly investigates Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer.
Her work focuses on many connections between Internal medicine and other disciplines, such as Surgery, that overlap with her field of interest in Gastroenterology.
Her research in Oncology intersects with topics in Trastuzumab, Chemotherapy, Phases of clinical research, Carboplatin and Hazard ratio.
Her Breast cancer research is multidisciplinary, relying on both Everolimus and Progression-free survival.
Her research investigates the connection between Cancer and topics such as Physical therapy that intersect with issues in Psychological intervention.
The Metastatic breast cancer study combines topics in areas such as Taxane, Capecitabine, Hormone receptor, Disease and Bevacizumab.
Her most cited work include:
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer (2040 citations)
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy (1201 citations)
- Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer (1190 citations)
What are the main themes of her work throughout her whole career to date?
Hope S. Rugo mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer.
Internal medicine connects with themes related to Surgery in her study.
Hope S. Rugo has included themes like Taxane, Phases of clinical research, Hormone receptor, Letrozole and Clinical endpoint in her Oncology study.
She combines subjects such as Bevacizumab, Clinical trial, Adverse effect, Gynecology and Stage with her study of Breast cancer.
She studied Metastatic breast cancer and Vinorelbine that intersect with Gemcitabine and Eribulin.
Hope S. Rugo has researched Chemotherapy in several fields, including Gastroenterology and Randomized controlled trial.
She most often published in these fields:
- Internal medicine (73.05%)
- Oncology (60.84%)
- Breast cancer (54.00%)
What were the highlights of her more recent work (between 2019-2021)?
- Internal medicine (73.05%)
- Oncology (60.84%)
- Breast cancer (54.00%)
In recent papers she was focusing on the following fields of study:
Her primary areas of investigation include Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer.
The Chemotherapy, Triple-negative breast cancer, Hazard ratio and Adverse effect research Hope S. Rugo does as part of her general Internal medicine study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
Her Oncology research also works with subjects such as
- Pembrolizumab, which have a strong connection to Carboplatin and Randomized controlled trial,
- Palbociclib which connect with Letrozole.
Neutropenia is closely connected to Gastroenterology in her research, which is encompassed under the umbrella topic of Breast cancer.
Her studies in Cancer integrate themes in fields like Cancer research and Talazoparib.
Her research integrates issues of Taxane, Regimen, Progressive disease and Capecitabine in her study of Metastatic breast cancer.
Between 2019 and 2021, her most popular works were:
- Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology (367 citations)
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial (299 citations)
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. (136 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Her primary areas of study are Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy.
Internal medicine is frequently linked to Placebo in her study.
Her studies in Oncology integrate themes in fields like Pembrolizumab, Gemcitabine, Trastuzumab and Palbociclib.
She focuses mostly in the field of Breast cancer, narrowing it down to matters related to Gastroenterology and, in some cases, Clinical endpoint.
Her work in the fields of Cancer, such as Fulvestrant and Aromatase inhibitor, intersects with other areas such as Cyclin-dependent kinase 4.
Her Chemotherapy study incorporates themes from Talazoparib, Veliparib, Olaparib and PARP inhibitor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
